# Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

> **NCT04333628** · PHASE2,PHASE3 · TERMINATED · sponsor: **HaEmek Medical Center, Israel** · enrollment: 5 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** chloroquine
- **OTHER:** standard care

## Key facts

- **NCT ID:** NCT04333628
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Teminated due to changes in treatment guidelines .
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333628, "Chloroquine for Mild Symptomatic and Asymptomatic COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04333628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*